The fact that MSH6 mutations were overrepresented among patients with breast carcinomas (7/23, 30%) versus other tumors (4/105, 4%) might have some influence on the results since the percentage of MMR-deficient breast carcinomas was lower among MSH6 than MSH2 or MLH1 mutation carriers (Table 2). Here, MSH6 is linked to breast carcinoma.